BioStock: Stayble enrols the first patient in herniated disc study
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Nyhetsbrev: Analys: Står sig Nordnet och Avanza i allt hårdare konkurrens? / Storbankens nya prognos: Styrräntan behöver sänkas till 1,5 procent

Pressmeddelande

BioStock: Stayble enrols the first patient in herniated disc study

Cision Publicerad: 04 Sep 2023 10:26
Stayble Therapeutics

Stayble has now enrolled and treated the first patient in the company’s clinical phase Ib study with STA363 for the treatment of herniated discs. This milestone marks a continued positive development for the drug candidate STA363, which is already undergoing a phase IIb study for degenerative disc disease. The company’s CEO Andreas Gerward shared his thoughts on the milestone in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/stayble-enrols-the-first-patient-in-herniated-disc-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Stayble Therapeutics

Läses av andra just nu

Om aktien Stayble Therapeutics

Senaste nytt